<p>Relmada Therapeutics, Inc. (NASDAQ:RLMD - 获取免费报告) 的股价在周一交易中创下了新的 52 周高点。该公司的股价最高达到 7.05 美元，最后交易价格为 6.9830 美元，成交量为 38414993 股。该股票之前的收盘价为 4.45 美元。</p>
<p>获取 <strong>Relmada Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>多位股票研究分析师最近对该公司进行了评估。Weiss Ratings 在 1 月 28 日的研究报告中重申了对 Relmada Therapeutics 股票的 “卖出（e+）” 评级。Jefferies Financial Group 在 12 月 22 日的报告中开始覆盖 Relmada Therapeutics 的股票。他们给予了 “买入” 评级，并设定了 9.00 美元的目标价。Lucid Cap Mkts 在 3 月 2 日的研究报告中将 Relmada Therapeutics 的股票评级上调至 “强力买入”。Mizuho 在 11 月 19 日的报告中将 Relmada Therapeutics 的评级从 “中性” 上调至 “跑赢大盘”，并将其目标价从 1.00 美元提高至 10.00 美元。最后，Leerink Partners 在 1 月 23 日的研究报告中将 Relmada Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并设定了 8.00 美元的目标价。一位研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 9.00 美元。</p>
<p><strong>查看我们关于 RLMD 的最新报告</strong></p>
<h2>Relmada Therapeutics 价格表现</h2>
<p>该股票的 50 日移动平均线为 4.13 美元，200 日移动平均线为 3.21 美元。该股票的市值为 5.3438 亿美元，市盈率为-4.07，贝塔值为 0.72。</p>
<h2>Relmada Therapeutics 内部活动</h2>
<p>在相关消息中，首席财务官 Maged Shenouda 在 12 月 15 日的交易中购买了 11665 股该公司的股票。股票的平均购买价格为每股 4.12 美元，总交易额为 48059.80 美元。收购后，首席财务官持有该公司 800,000 股股票，估值约为 329 万美元。这笔交易代表了他们持股比例的 1.48% 的增加。该收购已在向 SEC 的备案中披露，相关文件可通过此链接获取。公司内部人士持有该公司 20.70% 的股份。</p>
<h2>对 Relmada Therapeutics 的对冲基金观点</h2>
<p>多家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Janus Henderson Group PLC 在第四季度收购了 Relmada Therapeutics 的新头寸，价值约为 35041000 美元。Squadron Capital Management LLC 在第四季度购买了 Relmada Therapeutics 的新头寸，价值为 32361000 美元。Adage Capital Partners GP L.L.C.在第四季度收购了 Relmada Therapeutics 的新股份，价值为 20624000 美元。Spruce Street Capital LP 在第四季度购买了 Relmada Therapeutics 的新股份，价值为 19736000 美元。最后，Marshall Wace LLP 在第四季度将其在 Relmada Therapeutics 的股份增加了 1072.4%。Marshall Wace LLP 现在拥有 3189662 股该公司的股票，价值为 15406000 美元，此前在上个季度又收购了 2917609 股。目前，45.24% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>关于 Relmada Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Relmada Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于疼痛和其他中枢神经系统（CNS）疾病的新疗法。该公司采用专有的立体化学方法来优化药物候选物，旨在提高安全性、耐受性和疗效，与现有治疗相比。Relmada 的研究工作集中在调节 NMDA 受体，以满足抑郁症、神经性疼痛及相关适应症的未满足需求。</p>
<p>Relmada 的主要产品候选药物 REL-1017（d-美沙酮）正在评估作为潜在的快速作用和维持治疗重度抑郁症的疗法，目前正在进行临床研究，以评估其在急性和长期环境中的有效性。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Relmada Therapeutics 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Relmada Therapeutics 吗？</h2>
<p>在你考虑投资 Relmada Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Relmada Therapeutics 并不在名单上。</p>
<p>虽然 Relmada Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医药突破 ETF - ALPS

医疗业 ETF - Vanguard

标普生物技术 ETF - SPDR

<p>Relmada Therapeutics（纳斯达克代码：RLMD）达到了新的 52 周高点 7.05 美元，收盘价为 6.9830 美元，交易量显著。分析师的评级意见不一：Weiss Ratings 维持 “卖出” 评级，而 Jefferies 和 Lucid Cap Mkts 则给予 “买入” 评级，目标价为 9.00 美元及以上。该股票的市值为 5.3438 亿美元，市盈率为-4.07。内部交易显示首席财务官 Maged Shenouda 增加了持股，机构投资者持有 45.24% 的股份。Relmada 专注于开发中枢神经系统疾病的治疗，特别是针对抑郁症和疼痛的疗法</p>

<p>Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report)'s stock price hit a new 52-week high during trading on Monday . The company traded as high as $7.05 and last traded at $6.9830, with a volume of 38414993 shares. The stock had previously closed at $4.45.</p>
<div class="lb-trans"><p>Relmada Therapeutics, Inc. (NASDAQ:RLMD - 获取免费报告) 的股价在周一交易中创下了新的 52 周高点。该公司的股价最高达到 7.05 美元，最后交易价格为 6.9830 美元，成交量为 38414993 股。该股票之前的收盘价为 4.45 美元。</p>
</div><p>Get <strong>Relmada Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Relmada Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th. Jefferies Financial Group started coverage on shares of Relmada Therapeutics in a report on Monday, December 22nd. They issued a &#34;buy&#34; rating and a $9.00 price target on the stock. Lucid Cap Mkts upgraded shares of Relmada Therapeutics to a &#34;strong-buy&#34; rating in a research note on Monday, March 2nd. Mizuho upgraded Relmada Therapeutics from a &#34;neutral&#34; rating to an &#34;outperform&#34; rating and increased their price objective for the company from $1.00 to $10.00 in a report on Wednesday, November 19th. Finally, Leerink Partners upgraded Relmada Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $8.00 target price on the stock in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $9.00.</p>
<div class="lb-trans"><p>多位股票研究分析师最近对该公司进行了评估。Weiss Ratings 在 1 月 28 日的研究报告中重申了对 Relmada Therapeutics 股票的 “卖出（e+）” 评级。Jefferies Financial Group 在 12 月 22 日的报告中开始覆盖 Relmada Therapeutics 的股票。他们给予了 “买入” 评级，并设定了 9.00 美元的目标价。Lucid Cap Mkts 在 3 月 2 日的研究报告中将 Relmada Therapeutics 的股票评级上调至 “强力买入”。Mizuho 在 11 月 19 日的报告中将 Relmada Therapeutics 的评级从 “中性” 上调至 “跑赢大盘”，并将其目标价从 1.00 美元提高至 10.00 美元。最后，Leerink Partners 在 1 月 23 日的研究报告中将 Relmada Therapeutics 的评级从 “市场表现” 上调至 “跑赢大盘”，并设定了 8.00 美元的目标价。一位研究分析师给予该股票 “强力买入” 评级，三位给予 “买入” 评级，一位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 9.00 美元。</p>
</div><p><strong>View Our Latest Report on RLMD</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 RLMD 的最新报告</strong></p>
</div><h2>Relmada Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Relmada Therapeutics 价格表现</h2>
</div><p>The stock has a fifty day moving average of $4.13 and a 200 day moving average of $3.21. The stock has a market cap of $534.38 million, a price-to-earnings ratio of -4.07 and a beta of 0.72.</p>
<div class="lb-trans"><p>该股票的 50 日移动平均线为 4.13 美元，200 日移动平均线为 3.21 美元。该股票的市值为 5.3438 亿美元，市盈率为-4.07，贝塔值为 0.72。</p>
</div><h2>Insider Activity at Relmada Therapeutics</h2>
<div class="lb-trans"><h2>Relmada Therapeutics 内部活动</h2>
</div><p>In related news, CFO Maged Shenouda bought 11,665 shares of the company's stock in a transaction that occurred on Monday, December 15th. The stock was purchased at an average price of $4.12 per share, for a total transaction of $48,059.80. Following the acquisition, the chief financial officer owned 800,000 shares of the company's stock, valued at approximately $3,296,000. This trade represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 20.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席财务官 Maged Shenouda 在 12 月 15 日的交易中购买了 11665 股该公司的股票。股票的平均购买价格为每股 4.12 美元，总交易额为 48059.80 美元。收购后，首席财务官持有该公司 800,000 股股票，估值约为 329 万美元。这笔交易代表了他们持股比例的 1.48% 的增加。该收购已在向 SEC 的备案中披露，相关文件可通过此链接获取。公司内部人士持有该公司 20.70% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Relmada Therapeutics</h2>
<div class="lb-trans"><h2>对 Relmada Therapeutics 的对冲基金观点</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Janus Henderson Group PLC acquired a new position in Relmada Therapeutics in the fourth quarter valued at approximately $35,041,000. Squadron Capital Management LLC purchased a new position in shares of Relmada Therapeutics in the 4th quarter valued at $32,361,000. Adage Capital Partners GP L.L.C. acquired a new stake in Relmada Therapeutics during the 4th quarter worth $20,624,000. Spruce Street Capital LP purchased a new stake in Relmada Therapeutics in the fourth quarter valued at $19,736,000. Finally, Marshall Wace LLP boosted its stake in Relmada Therapeutics by 1,072.4% in the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company's stock valued at $15,406,000 after acquiring an additional 2,917,609 shares in the last quarter. 45.24% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近买入和卖出了该公司的股票。Janus Henderson Group PLC 在第四季度收购了 Relmada Therapeutics 的新头寸，价值约为 35041000 美元。Squadron Capital Management LLC 在第四季度购买了 Relmada Therapeutics 的新头寸，价值为 32361000 美元。Adage Capital Partners GP L.L.C.在第四季度收购了 Relmada Therapeutics 的新股份，价值为 20624000 美元。Spruce Street Capital LP 在第四季度购买了 Relmada Therapeutics 的新股份，价值为 19736000 美元。最后，Marshall Wace LLP 在第四季度将其在 Relmada Therapeutics 的股份增加了 1072.4%。Marshall Wace LLP 现在拥有 3189662 股该公司的股票，价值为 15406000 美元，此前在上个季度又收购了 2917609 股。目前，45.24% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>About Relmada Therapeutics</h2>
<div class="lb-trans"><h2>关于 Relmada Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada's research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.</p>
<div class="lb-trans"><p>Relmada Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于开发用于疼痛和其他中枢神经系统（CNS）疾病的新疗法。该公司采用专有的立体化学方法来优化药物候选物，旨在提高安全性、耐受性和疗效，与现有治疗相比。Relmada 的研究工作集中在调节 NMDA 受体，以满足抑郁症、神经性疼痛及相关适应症的未满足需求。</p>
</div><p>Relmada's lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.</p>
<div class="lb-trans"><p>Relmada 的主要产品候选药物 REL-1017（d-美沙酮）正在评估作为潜在的快速作用和维持治疗重度抑郁症的疗法，目前正在进行临床研究，以评估其在急性和长期环境中的有效性。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Relmada Therapeutics</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>Elon Musk already made me a “wealthy man”</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Relmada Therapeutics 更好</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
<li>埃隆·马斯克已经让我成为 “富有的人”</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Relmada Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Relmada Therapeutics 吗？</h2>
</div><p>Before you consider Relmada Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Relmada Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relmada Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Relmada Therapeutics 并不在名单上。</p>
</div><p>While Relmada Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Relmada Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Relmada Therapeutics (NASDAQ:RLMD) Reaches New 12-Month High  - Should You Buy?

Market Beat

纳斯达克生物科技指数 ETF - iShares Nasdaq

美国制药 ETF - iShares

基因改革 ETF - ARK

Relmada Therapeutics

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

Relmada Therapeutics（纳斯达克股票代码：RLMD）创下 12 个月新高 - 你应该购买吗？